...
首页> 外文期刊>Journal of Medicinal Chemistry >Novel peptide conjugates for tumor-specific chemotherapy.
【24h】

Novel peptide conjugates for tumor-specific chemotherapy.

机译:用于肿瘤特异性化学疗法的新型肽结合物。

获取原文
获取原文并翻译 | 示例

摘要

One of the major problems in cancer chemotherapy are the severe side effects that limit the dose of the anticancer drugs because of their unselectivity for tumor versus normal cells. In the present work, we show that coupling of anthracyclines to peptides is a promising approach to obtain selectivity. The peptide-drug conjugate was designed to bind to specific receptors expressed on the tumor cells with subsequent internalization of the ligand-receptor complex. Neuropeptide Y (NPY), a 36-amino acid peptide of the pancreatic polypeptide family, was chosen as model peptide because NPY receptors are overexpressed in a number of neuroblastoma tumors and the thereof derived cell lines. Daunorubicin and doxorubicin, two widely used antineoplastic agents in tumor therapy, were covalently linked to NPY via two spacers that differ in stability: an acid-sensitive hydrazone bond at the 13-keto position of daunorubicin and a stable amide bond at the 3'-amino position of daunorubicin and doxorubicin. Receptor binding of these three conjugates ([C(15)]-NPY-Dauno-HYD, [C(15)]-NPY-Dauno-MBS, and [C(15)]-NPY-Doxo-MBS) was determined at the human neuroblastoma cell line SK-N-MC, which selectively expresses the NPY Y(1) receptor subtype, and cytotoxic activity was evaluated using a XTT-based colorimetric cellular cytotoxicity assay. The different conjugates were able to bind to the receptor with affinities ranging from 25 to 51 nM, but only the compound containing the acid-sensitive bond ([C(15)]-NPY-Dauno-HYD) showed cytotoxic activity comparable to the free daunorubicin. This cytotoxicity is Y(1) receptor-mediated as shown in blocking studies with BIBP 3226, because tumor cells that do not express NPY receptors were sensitive to free daunorubicin, but not to the peptide-drug conjugate. The intracellular distribution was investigated by confocal laser scanning microscopy. We found evidence that the active conjugate [C(15)]-NPY-Dauno-HYD releases daunorubicin, which is localized close to the nucleus, whereas the inactive conjugate [C(15)]-NPY-Dauno-MBS is distributed distantly from the nucleus and does not seem to release the drug within the cell.
机译:癌症化学疗法的主要问题之一是严重的副作用,这限制了抗癌药物的剂量,因为它们对肿瘤细胞和正常细胞的选择性不高。在目前的工作中,我们表明蒽环类药物与肽的偶联是一种获得选择性的有前途的方法。肽-药物缀合物被设计为结合于肿瘤细胞上表达的特定受体,随后配体-受体复合物的内在化。神经肽Y(NPY)是胰腺多肽家族的36个氨基酸的肽,被选作模型肽,因为NPY受体在许多成神经细胞瘤肿瘤及其衍生的细胞系中过表达。柔红霉素和阿霉素(两种在肿瘤治疗中广泛使用的抗肿瘤药)通过两个在稳定性上不同的间隔基与NPY共价连接:在柔红霉素的13-酮位有一个酸敏感的bond键,在3'-处有一个稳定的酰胺键。柔红霉素和阿霉素的氨基位置。确定这三种结合物([C(15)]-NPY-Dauno-HYD,[C(15)]-NPY-Dauno-MBS和[C(15)]-NPY-Doxo-MBS)的受体结合人神经母细胞瘤细胞系SK-N-MC选择性表达NPY Y(1)受体亚型,并使用基于XTT的比色细胞细胞毒性试验评估了细胞毒性活性。不同的结合物能够以25到51 nM的亲和力与受体结合,但是只有含有酸敏感键的化合物([C(15)]-NPY-Dauno-HYD)才显示出与游离酸相当的细胞毒活性。柔红霉素。如BIBP 3226的阻断研究所示,这种细胞毒性是Y(1)受体介导的,因为不表达NPY受体的肿瘤细胞对游离柔红霉素敏感,但对肽-药物偶联物不敏感。通过共聚焦激光扫描显微镜研究细胞内分布。我们发现有证据表明,活性结合物[C(15)]-NPY-Dauno-HYD释放柔红霉素,其定位在靠近细胞核的位置,而无活性结合物[C(15)]-NPY-Dauno-MBS的分布距离较远核,似乎不会在细胞内释放药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号